STRUCTURAL REQUIREMENTS FOR BISPHOSPHONATE ACTIONS IN-VITRO

被引:123
作者
VANBEEK, E [1 ]
HOEKSTRA, M [1 ]
VANDERUIT, M [1 ]
LOWIK, C [1 ]
PAPAPOULOS, S [1 ]
机构
[1] LEIDEN UNIV HOSP,DEPT ENDOCRINOL & METAB DIS,LEIDEN,NETHERLANDS
关键词
D O I
10.1002/jbmr.5650091206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the structural requirements for the binding of bisphosphonates to bone mineral and the relation between their affinity for bone and their effects on bone resorption in vitro. For this we used fetal mouse long bones in culture and bisphosphonates with variable R(1), and R(2) structures. In addition, we studied the effect of structural differences in the incorporation of calcium into bone. We found that bisphosphonates containing a hydroxyl group in the R(1) position have the highest affinity for bone mineral. This was related to their capacity to inhibit the incorporation of calcium into long bones but not to their antiresorptive potency. The latter was primarily determined by R(2). Furthermore, the effect of bisphosphonates on calcification, but not on resorption of bone explants, was mainly determined by the mode of addition. The continuous presence of bisphosphonate during culture inhibited calcification even at very low concentrations, but short incubation of the bones with relatively high concentrations had no effect. This is probably a result of differences in the availability of the compound to the process of calcification. Because, in vivo, the more potent bisphosphonates inhibit resorption without adversely affecting mineralization of the skeleton and they disappear rapidly from the circulation after administration, we suggest that cultures of bone explants incubated with bisphosphonates for short times rather than cultures in which the drugs are continuously present provide more accurate information about the in vivo effect of these compounds on both resorption and calcification.
引用
收藏
页码:1875 / 1882
页数:8
相关论文
共 23 条
  • [1] BENEDICT JJ, 1982, DISPHOSPHONATES BONE, P1
  • [2] BIJVOET OLM, 1989, CLIN DISORDERS BONE, P525
  • [3] BOONEKAMP PM, 1986, BONE MINER, V1, P27
  • [4] BOONEKAMP PM, 1987, BONE MINER, V2, P29
  • [5] INVITRO FORMATION OF OSTEOCLASTS FROM LONG-TERM CULTURES OF BONE-MARROW MONONUCLEAR PHAGOCYTES
    BURGER, EH
    VANDERMEER, JWM
    VANDEGEVEL, JS
    GRIBNAU, JC
    THESINGH, CW
    VANFURTH, R
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (06) : 1604 - 1614
  • [6] EBETINO FH, 1993, PHOSPHORUS SULFUR, V76, P151
  • [7] BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE
    FLEISCH, H
    [J]. DRUGS, 1991, 42 (06) : 919 - 944
  • [8] ROLE OF BISPHOSPHONATES IN METABOLIC BONE-DISEASES
    HAMDY, NAT
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1993, 4 (01) : 19 - 25
  • [9] BINDING OF PYROPHOSPHATE AND TWO DIPHOSPHONATES BY HYDROXYAPATITE CRYSTALS
    JUNG, A
    BISAZ, S
    FLEISCH, H
    [J]. CALCIFIED TISSUE RESEARCH, 1973, 11 (04): : 269 - 280
  • [10] Kanis, 1994, BONE MINERAL RES, P265